AdAlta and SYNthesis to form AdCella for advanced cancer treatments
Australian biotechnology company AdAlta has signed a memorandum of understanding (MOU) with SYNthesis BioVentures Fund (SYNBV) to explore the creation…
Australian biotechnology company AdAlta has signed a memorandum of understanding (MOU) with SYNthesis BioVentures Fund (SYNBV) to explore the creation…
Life sciences investment company Medicxi has partnered with Starpharma for the formation of Petalion Therapeutics to develop dendrimer-based oncology treatments.…
Edenbridge Pharmaceuticals has selected PANTHERx Rare to distribute Yargesa (miglustat) capsules for the treatment of Type 1 Gaucher disease. The…
Cellenkos has signed a sponsored research agreement with the Icahn School of Medicine at Mount Sinai Hospital, New York, US,…
Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in…
Alexion, AstraZeneca Rare Disease has received approval from the US Food and Drug Administration (FDA) for Voydeya (danicopan) as an…
Alebund Pharmaceuticals has received the US Food and Drug Administration’s (FDA) orphan drug designation (ODD) for its investigational drug AP303.…
The US Food and Drug Administration (FDA) has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the…
Novartis has broken ground on the expansion of its biopharmaceutical manufacturing facility in Singapore, which aims to meet the increasing…
Astellas Pharma has submitted a supplemental new drug application (sNDA) in Japan seeking approval for the combination of Padcev (enfortumab…